Product Innovation - The fourth-generation hyaluronic acid product "Hai Mei Yue Bai" features human essential amino acids as cross-linking agents, significantly enhancing biocompatibility and long-term safety compared to traditional chemical cross-linkers [2] - The modification site of "Yue Bai" is the carboxyl group, which delays enzyme recognition, resulting in a longer maintenance time [2] - The introduction of amino acid cross-linking agents improves the traditional product's negative charge, promoting cell adhesion and proliferation, thus enhancing collagen generation [2] Market Strategy - The product's market preparation is progressing smoothly, with a nationwide pricing strategy aimed at the mid-to-high-end market [2] - The company emphasizes incremental sales growth without cannibalizing existing products like "Hai Mei" [2] - The company is actively participating in OEM sales, enhancing its market presence and product diversity [3] Business Development - The company is experiencing rapid growth in its third-generation hyaluronic acid product "Hai Mei," with a focus on maintaining market share and brand influence [2] - The integration of energy devices and biological materials is part of a comprehensive skin rejuvenation solution [3] - The company is expanding its product matrix beyond hyaluronic acid to include energy devices and other innovative materials [3] Research and Development - The company's R&D strategy includes three approaches: "Me too," "Me better," and "Me only," focusing on comprehensive skin rejuvenation [3] - Current R&D projects include enhanced water light injectables and medical-grade chitosan gels, aiming for product diversification [3] - The company is actively developing a range of products, including pain-free cross-linked sodium hyaluronate gels [3] Competitive Landscape - The company is strategically positioning itself in the competitive hyaluronic acid market by continuously launching innovative products [3] - The focus on product differentiation and effective marketing strategies has led to significant growth in the medical aesthetics sector [3]
昊海生科(688366) - 昊海生科2024年7月15日投资者关系活动记录表